NO20074149L - Nye farmasoytiske sammensetninger for behandling av trombose - Google Patents

Nye farmasoytiske sammensetninger for behandling av trombose

Info

Publication number
NO20074149L
NO20074149L NO20074149A NO20074149A NO20074149L NO 20074149 L NO20074149 L NO 20074149L NO 20074149 A NO20074149 A NO 20074149A NO 20074149 A NO20074149 A NO 20074149A NO 20074149 L NO20074149 L NO 20074149L
Authority
NO
Norway
Prior art keywords
antagonists
inhibitors
thrombosis
treatment
pharmaceutical compositions
Prior art date
Application number
NO20074149A
Other languages
English (en)
Norwegian (no)
Inventor
James C Gilbert
Paul A Reilly
Thomas H Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20074149(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20074149L publication Critical patent/NO20074149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20074149A 2005-03-29 2007-08-10 Nye farmasoytiske sammensetninger for behandling av trombose NO20074149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29
PCT/EP2006/061046 WO2006103206A2 (en) 2005-03-29 2006-03-27 Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis

Publications (1)

Publication Number Publication Date
NO20074149L true NO20074149L (no) 2007-12-11

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074149A NO20074149L (no) 2005-03-29 2007-08-10 Nye farmasoytiske sammensetninger for behandling av trombose

Country Status (19)

Country Link
US (2) US20060222640A1 (enExample)
EP (1) EP1885354A2 (enExample)
JP (1) JP2008534552A (enExample)
KR (1) KR20070116936A (enExample)
CN (1) CN101151030A (enExample)
AR (1) AR056291A1 (enExample)
AU (1) AU2006228600A1 (enExample)
BR (1) BRPI0608656A2 (enExample)
CA (1) CA2602563A1 (enExample)
CL (1) CL2010000395A1 (enExample)
EA (1) EA015122B1 (enExample)
IL (1) IL186267A0 (enExample)
MX (1) MX2007010664A (enExample)
NO (1) NO20074149L (enExample)
NZ (1) NZ562775A (enExample)
TW (1) TW200722089A (enExample)
UA (1) UA92603C2 (enExample)
WO (1) WO2006103206A2 (enExample)
ZA (1) ZA200706698B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20080274166A1 (en) * 2005-06-10 2008-11-06 Transpharma Medical Ltd. Patch for Transdermal Drug Delivery
WO2008009639A2 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
EP2074112A1 (en) * 2006-10-10 2009-07-01 Boehringer Ingelheim International GmbH Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US20100293807A1 (en) * 2007-10-29 2010-11-25 Transpharma Medical, Ltd. Vertical patch drying
US20110236405A1 (en) * 2008-07-29 2011-09-29 Tel Hashomer Medical Research Infrastructure And Services Ltd. Coagulation factor modulation for controlling transplant organ size
CA2735983A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
CN103463083A (zh) * 2008-11-11 2013-12-25 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良有效性的方法
AU2009315731A1 (en) * 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
CN102209544A (zh) * 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良安全性的方法
JP5851246B2 (ja) 2008-12-30 2016-02-03 リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
CN103402527B (zh) * 2011-01-25 2016-04-20 鲁汶大学 用于细胞移植的组合物和方法
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
JP6034406B2 (ja) * 2012-01-25 2016-11-30 ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ 細胞移植のための組成物および方法
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
EP2722034B1 (en) * 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
DK3016665T3 (da) 2013-07-05 2019-11-25 Univ Catholique Louvain Konditioneret medium fra humane voksne leverstamceller og dets anvendelse i behandlingen af leverlidelser
DE102014108210A1 (de) * 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
US12251377B2 (en) 2019-03-06 2025-03-18 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN115192691B (zh) * 2022-08-31 2025-03-04 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
EP1437137B1 (en) * 2001-09-14 2008-12-31 Mitsubishi Tanabe Pharma Corporation Drugs comprising combination of antithrombotic agent with pyrazolone derivative
SI1870100T1 (sl) * 2002-03-07 2012-05-31 Boehringer Ingelheim Int Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
KR20060007034A (ko) * 2003-04-24 2006-01-23 베링거 인겔하임 인터내셔날 게엠베하 혈전색전증 질환 및 트롬빈의 과형성 및/또는 트롬빈수용체의 상승된 발현에 의해 유발된 질환 및 장애를치료하고 예방하기 위한, 디피리다몰 또는 모피다몰의 용도

Also Published As

Publication number Publication date
EA200701841A1 (ru) 2008-02-28
US20060222640A1 (en) 2006-10-05
WO2006103206A2 (en) 2006-10-05
UA92603C2 (ru) 2010-11-25
CN101151030A (zh) 2008-03-26
KR20070116936A (ko) 2007-12-11
CL2010000395A1 (es) 2010-08-20
EA015122B1 (ru) 2011-06-30
CA2602563A1 (en) 2006-10-05
BRPI0608656A2 (pt) 2010-01-19
AU2006228600A1 (en) 2006-10-05
NZ562775A (en) 2011-03-31
AR056291A1 (es) 2007-10-03
ZA200706698B (en) 2008-12-31
US20100184729A1 (en) 2010-07-22
MX2007010664A (es) 2007-12-12
TW200722089A (en) 2007-06-16
EP1885354A2 (en) 2008-02-13
WO2006103206A3 (en) 2007-01-11
IL186267A0 (en) 2008-01-20
JP2008534552A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
TW200722089A (en) New pharmaceutical compositions for treatment of thrombosis
NO20090835L (no) Nye HIV-reverstranskriptaseinhibitorer
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
EA201000329A1 (ru) Циклические депсипептиды
JOP20220085A1 (ar) مركبات أريل ميثيلين حلقية غير متجانسة على هيئة حاصرات قناة بوتاسيوم Kv1.3 بجين شاكر
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
CO5580771A2 (es) Antagonistas ccr5 como agentes terapeuticos
ECSP099269A (es) Compuestos de fenilurea como inhibidores de epóxido hidrolasa soluble
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE483707T1 (de) 2-cyclopropylthiazolderivate
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
ECSP088103A (es) Nuevos derivados de 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones de hiperlipidemia
ECSP078052A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
ECSP078051A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
NO20085212L (no) Nye pyridinanaloger
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
BRPI0713132B8 (pt) compostos derivados de cinamoil-piperazina, método de preparação dos referidos compostos, composições farmacêuticas, seus usos como antagonistas de par-i e produtos
WO2009004383A3 (en) Aza-bicyclohexane compounds useful as anticoagulants
NO20064160L (no) Nye azaibicykliske forbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
NO20084543L (no) Benzimidazolderivater
TW200745062A (en) Macrocyclic factor VIIA inhibitors useful as anticoagulants

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application